Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs4148325
rs4148325
C 0.800 GeneticVariation GWASCAT Genome-Wide Association Study (GWAS) on Bilirubin Concentrations in Subjects with Metabolic Syndrome: Sex-Specific GWAS Analysis and Gene-Diet Interactions in a Mediterranean Population. 30621171

2019

dbSNP: rs7564935
rs7564935
G 0.800 GeneticVariation GWASCAT Uganda Genome Resource Enables Insights into Population History and Genomic Discovery in Africa. 31675503

2019

dbSNP: rs929596
rs929596
G 0.800 GeneticVariation GWASCAT Genome-Wide Association Study (GWAS) on Bilirubin Concentrations in Subjects with Metabolic Syndrome: Sex-Specific GWAS Analysis and Gene-Diet Interactions in a Mediterranean Population. 30621171

2019

dbSNP: rs28946889
rs28946889
0.800 GeneticVariation GWASCAT Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. 29403010

2018

dbSNP: rs6431630
rs6431630
0.800 GeneticVariation GWASCAT Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. 29403010

2018

dbSNP: rs8330
rs8330
0.800 GeneticVariation GWASCAT Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. 29403010

2018

dbSNP: rs10178992
rs10178992
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs10179091
rs10179091
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs10929301
rs10929301
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs10929302
rs10929302
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs11673726
rs11673726
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs11695484
rs11695484
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs11888459
rs11888459
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs17862875
rs17862875
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs3755319
rs3755319
0.800 GeneticVariation GWASCAT Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. 25884002

2015

dbSNP: rs4148324
rs4148324
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs4148325
rs4148325
0.800 GeneticVariation GWASCAT Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. 25884002

2015

dbSNP: rs4148325
rs4148325
0.800 GeneticVariation GWASCAT We analyzed total bilirubin levels, which are linked to fatty liver in severe obesity, and observed the strongest evidence for association with rs4148325 in UGT1A (P < 5.0 × 10(-93)), replicating previous findings. 25246029

2015

dbSNP: rs4148325
rs4148325
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs4663969
rs4663969
0.800 GeneticVariation GWASCAT Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. 25884002

2015

dbSNP: rs6714634
rs6714634
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs6742078
rs6742078
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs7604115
rs7604115
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs887829
rs887829
0.800 GeneticVariation GWASCAT Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. 26148204

2015

dbSNP: rs887829
rs887829
T 0.800 GeneticVariation GWASCAT Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. 25884002

2015